David Gritsch, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aquaporin 4 | 3 | 2023 | 151 | 0.810 |
Why?
|
Spinal Muscular Atrophies of Childhood | 1 | 2023 | 110 | 0.800 |
Why?
|
Myelitis, Transverse | 1 | 2021 | 41 | 0.760 |
Why?
|
Craniopharyngioma | 1 | 2024 | 284 | 0.760 |
Why?
|
Embolism, Paradoxical | 1 | 2020 | 58 | 0.720 |
Why?
|
Foramen Ovale, Patent | 1 | 2020 | 224 | 0.600 |
Why?
|
Cerebrovascular Disorders | 2 | 2022 | 1514 | 0.590 |
Why?
|
Tissue Plasminogen Activator | 1 | 2022 | 1272 | 0.530 |
Why?
|
Pituitary Neoplasms | 1 | 2024 | 1354 | 0.510 |
Why?
|
Autoantibodies | 3 | 2022 | 2068 | 0.470 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1389 | 0.460 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 898 | 0.430 |
Why?
|
Estrogen Receptor alpha | 3 | 2011 | 588 | 0.420 |
Why?
|
Cyclin-Dependent Kinases | 3 | 2011 | 673 | 0.380 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1295 | 0.380 |
Why?
|
Brain Neoplasms | 2 | 2022 | 8947 | 0.380 |
Why?
|
S Phase | 1 | 2011 | 424 | 0.340 |
Why?
|
G1 Phase | 1 | 2011 | 414 | 0.340 |
Why?
|
Neuromyelitis Optica | 2 | 2023 | 258 | 0.340 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 630 | 0.340 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1770 | 0.330 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2112 | 0.320 |
Why?
|
Epilepsy | 1 | 2022 | 3319 | 0.270 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3164 | 0.250 |
Why?
|
Stroke | 3 | 2022 | 10152 | 0.250 |
Why?
|
Melanoma | 1 | 2022 | 5547 | 0.230 |
Why?
|
West Nile Fever | 1 | 2024 | 77 | 0.230 |
Why?
|
West Nile virus | 1 | 2024 | 79 | 0.230 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4280 | 0.230 |
Why?
|
Purines | 3 | 2011 | 594 | 0.220 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5469 | 0.220 |
Why?
|
Headache Disorders, Primary | 1 | 2022 | 36 | 0.210 |
Why?
|
Paresis | 1 | 2023 | 180 | 0.200 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2024 | 646 | 0.190 |
Why?
|
Hashimoto Disease | 1 | 2021 | 101 | 0.180 |
Why?
|
Upper Extremity | 1 | 2023 | 656 | 0.150 |
Why?
|
Encephalitis | 1 | 2021 | 429 | 0.150 |
Why?
|
Vena Cava, Inferior | 1 | 2020 | 445 | 0.150 |
Why?
|
Cervical Vertebrae | 1 | 2023 | 969 | 0.140 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 2125 | 0.140 |
Why?
|
Fatal Outcome | 1 | 2020 | 1859 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10057 | 0.130 |
Why?
|
Heart Atria | 1 | 2020 | 1356 | 0.120 |
Why?
|
Administration, Oral | 1 | 2022 | 3941 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11626 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2042 | 0.120 |
Why?
|
Central Nervous System | 1 | 2021 | 1362 | 0.120 |
Why?
|
Thrombolytic Therapy | 1 | 2022 | 2202 | 0.110 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5076 | 0.110 |
Why?
|
Drug Synergism | 3 | 2011 | 1768 | 0.110 |
Why?
|
Fibrinolytic Agents | 1 | 2022 | 2197 | 0.100 |
Why?
|
Humans | 21 | 2024 | 752741 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2022 | 1921 | 0.100 |
Why?
|
Tamoxifen | 3 | 2011 | 979 | 0.100 |
Why?
|
Headache | 3 | 2023 | 1238 | 0.090 |
Why?
|
Immunoblotting | 2 | 2011 | 1675 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1903 | 0.090 |
Why?
|
Quantitative Trait Loci | 1 | 2018 | 2049 | 0.090 |
Why?
|
Migraine Disorders | 1 | 2022 | 1645 | 0.090 |
Why?
|
Parkinson Disease | 1 | 2023 | 2822 | 0.090 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8660 | 0.080 |
Why?
|
Multiple Sclerosis | 1 | 2023 | 3118 | 0.080 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2011 | 414 | 0.080 |
Why?
|
Endovascular Procedures | 1 | 2021 | 2032 | 0.070 |
Why?
|
Brain Ischemia | 1 | 2021 | 3284 | 0.070 |
Why?
|
Anticoagulants | 1 | 2022 | 4738 | 0.070 |
Why?
|
Adult | 6 | 2024 | 216658 | 0.070 |
Why?
|
Adolescent | 3 | 2024 | 86713 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 35798 | 0.060 |
Why?
|
Brain | 3 | 2023 | 26598 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2011 | 2945 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2011 | 5974 | 0.060 |
Why?
|
Genetic Variation | 1 | 2018 | 6567 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9305 | 0.050 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6233 | 0.050 |
Why?
|
Quality of Life | 1 | 2024 | 13044 | 0.050 |
Why?
|
Minnesota | 1 | 2022 | 344 | 0.050 |
Why?
|
Xanthines | 1 | 2021 | 120 | 0.050 |
Why?
|
Middle Aged | 4 | 2024 | 216054 | 0.050 |
Why?
|
Male | 6 | 2024 | 354311 | 0.050 |
Why?
|
Vasoconstriction | 1 | 2022 | 596 | 0.040 |
Why?
|
Mutation | 1 | 2024 | 29981 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20346 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2022 | 64017 | 0.040 |
Why?
|
Mental Disorders | 1 | 2018 | 6699 | 0.040 |
Why?
|
Cell Proliferation | 2 | 2011 | 10508 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 936 | 0.040 |
Why?
|
Female | 6 | 2024 | 385090 | 0.040 |
Why?
|
Conscious Sedation | 1 | 2021 | 527 | 0.030 |
Why?
|
Dopamine | 1 | 2023 | 1584 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15433 | 0.030 |
Why?
|
Syndrome | 1 | 2022 | 3261 | 0.030 |
Why?
|
Young Adult | 1 | 2021 | 57267 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 5584 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2021 | 1178 | 0.030 |
Why?
|
Cell Cycle | 2 | 2011 | 2967 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1343 | 0.030 |
Why?
|
Dichlororibofuranosylbenzimidazole | 1 | 2011 | 16 | 0.020 |
Why?
|
G2 Phase | 1 | 2011 | 136 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2011 | 191 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4575 | 0.020 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2011 | 135 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3354 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 294 | 0.020 |
Why?
|
Aged | 1 | 2022 | 165629 | 0.020 |
Why?
|
Phosphorylation | 2 | 2011 | 8414 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2011 | 13678 | 0.020 |
Why?
|
Serine | 1 | 2011 | 825 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12423 | 0.020 |
Why?
|
Zebrafish | 1 | 2018 | 3000 | 0.020 |
Why?
|
RNA Polymerase II | 1 | 2011 | 548 | 0.020 |
Why?
|
Sleep | 1 | 2022 | 4619 | 0.020 |
Why?
|
Breast Neoplasms | 2 | 2011 | 20914 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3722 | 0.020 |
Why?
|
HeLa Cells | 1 | 2011 | 3125 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 21146 | 0.010 |
Why?
|
Estrogens | 1 | 2011 | 1573 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2024 | 78758 | 0.010 |
Why?
|
Estradiol | 1 | 2011 | 2025 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1517 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 40939 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5860 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 23554 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 12054 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3766 | 0.010 |
Why?
|
Animals | 2 | 2024 | 169600 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10914 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53863 | 0.010 |
Why?
|
United States | 1 | 2022 | 70772 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 16789 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 40195 | 0.010 |
Why?
|